<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01516996</url>
  </required_header>
  <id_info>
    <org_study_id>BT-IST-SCCHN-036</org_study_id>
    <nct_id>NCT01516996</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer</brief_title>
  <official_title>Neoadjuvant and Concurrent Chemoradiotherapy Plus Nimotuzumab in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Oropharynx and Hypopharynx</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Second People's Hospital of Sichuan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotech Pharmaceutical Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Second People's Hospital of Sichuan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficiency and safety of adding nimotuzumab to
      neoadjuvant and concurrent chemoradiotherapy in the treatment of patients with locoregionally
      advanced squamous cell carcinoma of the oropharynx and hypopharynx.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Locoregionally advanced squamous cell carcinoma of the head and neck(LA-SCCHN) poses one of
      the most complex management challenges. This stage of disease is still potentially curable,
      but requires combined-modality therapy. Recent studies have showed that induction
      chemotherapy（neoadjuvant）reduced the 3-year distant relapse rate. Concurrent
      chemoradiotherapy(CCRT), on the other hand, has demonstrated a significant and consistent
      benefit in local control rates, but its impact on distant failure is inconsistent.
      Nimotuzumab is a novel EGFR-targeting monoclonal antibody that has the potential.to be used
      as a single agent or as a radio- and chemotherapy sensitizer for the treatment of SCCHN.
      Thus, investigators conducted a randomized, multicenter phaseⅡ study to compare the
      efficiency and safety of adding nimotuzumab to neoadjuvant and CCRT with neoadjuvant and CCRT
      in the treatment of patients with locoregionally advanced squamous cell carcinoma of the
      oropharynx and hypopharynx.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>3 months after all the treatment ending</time_frame>
    <description>Objective Response Rate: Complete response (CR)+ partial response (PR) rates base on RECIST evaluation system.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Participants with Adverse Events</measure>
    <time_frame>Participants will be followed during the treatment and 3 months after all the treatment ending ,an expected average of 26 weeks</time_frame>
    <description>Record the Number of participants with adverse events and the Grades of the AE according to CTCAE v3.0 as the two measure of safety.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of randomization until the date of death from any cause,assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Local control Rate in 1 to 5 years.</measure>
    <time_frame>Participants will be followed every year for the duration of 5 years</time_frame>
    <description>To evaluate each year until 5 years later</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor-Free Survival</measure>
    <time_frame>From date of randomization until the date of first documented occurrence of primary, neck, distant relapse,assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-metastatic Rate</measure>
    <time_frame>The time from randomization until distant relapse occur,assessed up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Oropharyngeal Cancer</condition>
  <condition>Hypopharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant and CCRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant and CCRT and Nimotuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel and cisplatin</intervention_name>
    <description>The neoadjuvant consists of docetaxel 75mg/m2 day 1 and cisplatin 75mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.
CCRT: cisplatin 75mg/m2 is administered on day 1 of week 7,10 and 13 on current with RT</description>
    <arm_group_label>Neoadjuvant and CCRT</arm_group_label>
    <arm_group_label>Neoadjuvant and CCRT and Nimotuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>IMRT is administered with chemotherapy from week 7 to week 13
GTV（primary tumor）：68-70Gy/35~38 F，once a day, 5 times per week
CTV（Clinical target）：56-66Gy/30~36f，once a day, 5 times per week
GTV-ln（positive neck region）：66-70Gy/33~36 F，once a day, 5 times per week
CTV-ln（negative neck region）：50-54Gy/28~30F, once a day, 5 times</description>
    <arm_group_label>Neoadjuvant and CCRT</arm_group_label>
    <arm_group_label>Neoadjuvant and CCRT and Nimotuzumab</arm_group_label>
    <other_name>CCRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nimotuzumab</intervention_name>
    <description>Nimotuzumab was administered 200 mg IV over 1 hour on day 1,once a week, for 13~14 weeks</description>
    <arm_group_label>Neoadjuvant and CCRT and Nimotuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent form

          -  Histologically confirmed locally advanced (stages III and IVb), squamous cell
             carcinoma of the oropharynx and hypopharynx

          -  The tumor mass had to be measurable

          -  Karnofsky performance status ≥70

          -  Life expectancy estimated than 6 months

          -  Hematologic: WBC≥4×109 /L , plateletes≥100×109 /L, haemoglobin ≥100 g/L；

          -  Hepatic: AST/ALT＜1.5 times upper limit of normal (ULN)；serum bilirubin&lt;1.5 times ULN;

          -  Renal: Creatinine＜1.5 times ULN；

        Exclusion Criteria:

          -  Known distant metastases

          -  Primary tumor and nodes received surgery(except of biopsy)

          -  Received other anti EGFR monoclonal antibody treatment

          -  Previous chemotherapy or radiotherapy

          -  Participation in other interventional clinical trials within 1 month

          -  Other malignant tumor (except of non-melanoma skin Cancer or carcinoma in situ of
             cervix)

          -  History of serious allergic or allergy

          -  History of Serious lung or heart disease

          -  Pregnancy or lactation women, or women with suspected pregnancy or men with willing to
             get pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi J Lang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiotherapy department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gansu Province Medical Science Institute</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guangxi Tumor Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>GuiZhou Cancer Hospital</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neimenggu Tumor Hospital</name>
      <address>
        <city>Baotou</city>
        <state>Neimenggu</state>
        <zip>014030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Tumor Affiliated Hospital of Ningxia Medical University General Hospita</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>750004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Qinghai Five Hospital</name>
      <address>
        <city>Xining</city>
        <state>Qinghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xi-an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ShanXi Cancer Hospital</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second People's Hospital of Sichuan</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Xu, M.D.</last_name>
      <phone>15828312322</phone>
      <email>xupeng4618@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Sichuan</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xinjiang tumor hospital, The Third Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Wulumuqi</city>
        <state>Xinjiang</state>
        <zip>830000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yunnan Tumor Hospital, The Third Affiliated Hospital of KUNMING Medical University</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>652100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2012</study_first_submitted>
  <study_first_submitted_qc>January 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2012</study_first_posted>
  <last_update_submitted>March 18, 2012</last_update_submitted>
  <last_update_submitted_qc>March 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Second People's Hospital of Sichuan</investigator_affiliation>
    <investigator_full_name>LANG Jin-yi</investigator_full_name>
    <investigator_title>Professor of radiotherapy department</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant</keyword>
  <keyword>Concurrent Chemoradiotherapy,CCRT</keyword>
  <keyword>Nimotuzumab</keyword>
  <keyword>Locoregionally Advanced Oropharynx</keyword>
  <keyword>Hypopharynx cancer</keyword>
  <keyword>Randomized</keyword>
  <keyword>Multicenter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Hypopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

